|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
134,986 |
251,929 |
319,053 |
656,089 |
Total Sell Value |
$11,097,511 |
$21,508,551 |
$27,661,182 |
$61,420,002 |
Total People Sold |
5 |
6 |
7 |
7 |
Total Sell Transactions |
9 |
19 |
27 |
56 |
End Date |
2024-04-04 |
2024-01-02 |
2023-07-04 |
2022-07-04 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-05-08 |
4 |
AS |
$93.17 |
$465,850 |
D/D |
(5,000) |
238,496 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-05-08 |
4 |
OE |
$17.33 |
$86,650 |
D/D |
5,000 |
243,496 |
|
- |
|
Meier Richard A |
Director |
|
2017-05-05 |
4 |
OE |
$17.33 |
$129,975 |
D/D |
7,500 |
34,260 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2017-05-05 |
4 |
AS |
$99.00 |
$444,114 |
D/D |
(4,486) |
51,532 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2017-05-05 |
4 |
OE |
$28.23 |
$162,879 |
D/D |
4,486 |
55,030 |
|
- |
|
Davis George Eric |
EVP, General Counsel |
|
2017-05-05 |
4 |
AS |
$100.34 |
$250,852 |
D/D |
(2,500) |
85,251 |
|
- |
|
Davis George Eric |
EVP, General Counsel |
|
2017-05-05 |
4 |
OE |
$38.59 |
$96,475 |
D/D |
2,500 |
87,751 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-05-05 |
4 |
AS |
$99.00 |
$495,000 |
D/D |
(5,000) |
238,496 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-05-05 |
4 |
OE |
$17.33 |
$86,650 |
D/D |
5,000 |
243,496 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2017-05-02 |
4 |
AS |
$96.74 |
$29,215 |
D/D |
(302) |
51,532 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2017-04-28 |
4 |
A |
$70.30 |
$10,897 |
D/D |
155 |
26,826 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2017-04-28 |
4 |
A |
$70.30 |
$21,232 |
D/D |
302 |
147,793 |
|
- |
|
Fuchs Henry J |
President, Worldwide R&D |
|
2017-04-28 |
4 |
A |
$70.30 |
$21,232 |
D/D |
302 |
140,494 |
|
- |
|
Mueller Brian |
SVP, Corporate Controller |
|
2017-04-28 |
4 |
A |
$70.30 |
$18,982 |
D/D |
270 |
18,350 |
|
- |
|
Davis George Eric |
EVP, General Counsel |
|
2017-04-28 |
4 |
A |
$70.30 |
$21,232 |
D/D |
302 |
85,251 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-04-28 |
4 |
A |
$70.30 |
$21,232 |
D/D |
302 |
238,496 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2017-04-28 |
4 |
A |
$70.30 |
$21,232 |
D/D |
302 |
51,834 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-04-27 |
4 |
AS |
$95.72 |
$478,600 |
D/D |
(5,000) |
238,194 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-04-27 |
4 |
OE |
$17.33 |
$86,650 |
D/D |
5,000 |
243,194 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-04-25 |
4 |
AS |
$94.00 |
$470,000 |
D/D |
(5,000) |
238,194 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-04-25 |
4 |
OE |
$17.33 |
$86,650 |
D/D |
5,000 |
243,194 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-04-04 |
4 |
OE |
$14.39 |
$43,170 |
D/D |
3,000 |
238,194 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2017-03-29 |
4 |
AS |
$89.15 |
$346,794 |
D/D |
(3,890) |
51,532 |
|
- |
|
Davis George Eric |
EVP, General Counsel |
|
2017-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
11,220 |
84,949 |
|
- |
|
Fuchs Henry J |
President, Worldwide R&D |
|
2017-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
19,790 |
140,192 |
|
- |
|
1285 Records found
|
|
Page 35 of 52 |
|
|